EV / EBITDA společnosti SinoMab BioScience
Jaká je hodnota metriky EV / EBITDA společnosti SinoMab BioScience?
Hodnota metriky EV / EBITDA společnosti SinoMab BioScience Limited je N/A
Jaká je definice metriky EV / EBITDA?
EV/EBITDA je podniková hodnota dělená EBITDA (zisk před odečtením úroků, daní, odpisů a amortizací). Měří nákladnost akcie a používá se k porovnání společností mezi sebou častěji než P/E ratio. Měří cenu, jakou investor zaplatí za pohyb hotovosti ve společnosti.
Price to earnings ratios are impacted by a company's choice of capital structure - companies which raise money via debt will have lower P/Es (and therefore look cheaper) than companies that raise an equivalent amount of money by issuing shares, even though the two companies might have equivalent enterprise values. A sample case is when a company with debt were to raise money by issuing shares of stock, and then used the money to pay off the debt, this company's P/E ratio would shoot up because of the increased number of shares - although nothing about the fundamental value of the business has changed. EV / EBITDA is unaffected by capital structure as enterprise value includes the value of debt, and EBITDA is available to all investors (debt and equity) as it excludes interest payments on that debt. It is ideal for analysts and potential investors looking to compare companies within the same industry.
EV / EBITDA společností v sektoru Health Care sektor na HKSE ve srovnání se společností SinoMab BioScience
Čemu se věnuje společnost SinoMab BioScience?
SinoMab BioScience Limited, a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of therapeutics for the treatment of immunological diseases, primarily monoclonal antibody (mAb)-based biologics. Its flagship product is SM03, a first-in-target anti-CD22 mAb, which is in Phase III clinical trial for the treatment of rheumatoid arthritis (RA), as well as in various clinical stages for other immunological diseases, such as systemic lupus erythematosus (SLE), Sjogren's syndrome (SS), and non-Hodgkin's lymphoma (NHL). The company also focuses on developing SN1011, a Bruton's tyrosine kinase inhibitor, which is Phase I clinical trial for the treatment of RA, SLE, pemphigus, multiple sclerosis, and other immunological diseases. Its products under preclinical stage comprise SM17 for the treatment of asthma and idiopathic pulmonary fibrosis; SM09 that is used for the treatment of NHL and RA; SM06 for use in treating RA, SLE, and SS; and TNF2 for the treatment of RA. The company operates in Mainland China, the Cayman Islands, and Hong Kong. SinoMab BioScience Limited was incorporated in 2001 and is headquartered in Pak Shek Kok, Hong Kong.
Firmy s metrikou ev / ebitda podobnou společnosti SinoMab BioScience
- Hodnota metriky EV / EBITDA společnosti Novavax je N/A
- Hodnota metriky EV / EBITDA společnosti Cazaly Resources je N/A
- Hodnota metriky EV / EBITDA společnosti DC Acquisition je N/A
- Hodnota metriky EV / EBITDA společnosti Macarthur Minerals je N/A
- Hodnota metriky EV / EBITDA společnosti Sierra Madre Gold and Silver je N/A
- Hodnota metriky EV / EBITDA společnosti Rathdowney Resources je N/A
- Hodnota metriky EV / EBITDA společnosti SinoMab BioScience je N/A
- Hodnota metriky EV / EBITDA společnosti Big Dougie Capital je N/A
- Hodnota metriky EV / EBITDA společnosti Income Trust je N/A
- Hodnota metriky EV / EBITDA společnosti Aloro Mining je N/A
- Hodnota metriky EV / EBITDA společnosti Manganese X je N/A
- Hodnota metriky EV / EBITDA společnosti Coho Collective Kitchens je N/A
- Hodnota metriky EV / EBITDA společnosti Viva Gold je N/A